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Sal-like 4 (SALL4) is a nuclear factor central to the maintenance of
stem cell pluripotency and is a key component in hepatocellular
carcinoma, a malignancy with no effective treatment. In cancer cells,
SALL4 associates with nucleosome remodeling deacetylase (NuRD)
to silence tumor-suppressor genes, such as PTEN. Here, we deter-
mined the crystal structure of an amino-terminal peptide of SALL4
(1–12) complexed to RBBp4, the chaperone subunit of NuRD, at
2.7 Å, and subsequent design of a potent therapeutic SALL4 peptide
(FFW) capable of antagonizing the SALL4–NURD interaction using
systematic truncation and amino acid substitution studies. FFW pep-
tide disruption of the SALL4–NuRD complex resulted in unidirec-
tional up-regulation of transcripts, turning SALL4 from a dual
transcription repressor-activator mode to singular transcription ac-
tivator mode. We demonstrate that FFW has a target affinity of
23 nM, and displays significant antitumor effects, inhibiting tumor
growth by 85% in xenograft mouse models. Using transcriptome
and survival analysis, we discovered that the peptide inhibits the
transcription-repressor function of SALL4 and causes massive up-
regulation of transcripts that are beneficial to patient survival. This
study supports the SALL4–NuRD complex as a drug target and FFW
as a viable drug candidate, showcasing an effective strategy to
accurately target oncogenes previously considered undruggable.
SALL4 | RBBp4/NuRD | peptidomimetic | HCC | structural guided design
Sal-like 4 (SALL4) is a nuclear factor central to the mainte-nance of stem cell pluripotency (1–3), specifically expressed in
fetal cells. SALL4 is down-regulated or absent in most adult tis-
sues but is reactivated in solid (4–7) and hematological malig-
nancies (8–11), often associated with poor prognosis (12–14). In
embryonic stem cells, SALL4 forms a core transcriptional network
with Oct4, Nanog, and Sox2 to drive embryonic stem cell (ESC)
self-renewal (1–3). It was also observed that SALL4 plays a dual
role in transcription activity in ESCs, activating self-renewal and
repressing differentiation related transcripts at the same time (2,
15). Recently, we and others found that activation of SALL4 is a
key driver in up to 55% of hepatocellular carcinoma (HCC) pa-
tients (14, 16, 17). It also serves as a biomarker for progenitor-like
HCC (14, 16), an aggressive subset of HCC characterized by stem
cell features, invasive potential, and poor patient prognosis (17).
In HCC, we reported that the phosphatase and tensin homolog
deleted on chromosome 10 (PTEN)–AKT-PI3K pathway is al-
tered by the reexpression of SALL4 (16). Furthermore, we have
also reported that SALL4 acts as a repressor of PTEN by
recruiting the nucleosome remodeling deacetylase (NuRD) com-
plex (18). NuRD is a chromatin remodeling complex that silences
key regulators in ESCs and adult cells (19, 20); it has two in-
dependent enzymatic activities whereby nucleosomes are reposi-
tioned by the CDH3/4 ATPase subunits in order for the histone
deacetylase (HDAC1/2) subunits to access their targets and re-
press target genes. The retinoblastoma binding protein 4 (RBBp4)
is a subunit of NuRD. It is a WD40 repeat-containing protein,
which consists of a seven-bladed β‐propeller domain. In NuRD,
RBBp4 acts as a chaperone in nucleosome assembly by bringing
together histones H3 and H4 onto newly replicated DNA (21).
HCC is a fast-growing malignancy with a median survival of
11 mo. With less than 30% of patients able to receive potentially
curative treatments like surgery and liver transplant, it is now the
second leading cause of death worldwide (globocan.iarc.fr/) due
to the lack of effective treatment options for the majority of
HCC patients. The multikinase inhibitor Sorafenib is currently
the first-line treatment available for patients with advanced
HCC. However, this drug shows frequent adverse effects and
only prolongs survival for an average of 3 mo (22). Promising
new drugs that have reached clinical trials so far have met with
failure. Therefore, there is an urgent need to explore alterna-
tive approaches for the treatment of this deadly disease. SALL4,
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however, falls into the class of what is termed as “undruggable”
targets, as a nuclear factor lacking a typical, druggable pocket for
inhibitor binding. In this report, we discovered that the SALL4–
NuRD interaction offers an intriguing potential therapeutic tar-
get, as SALL4 is expressed uniquely in a selected population of
cancer cells with poor prognosis, and not in normal adult cells.
Furthermore, we demonstrated that by targeting SALL4–NuRD,
we are able to reverse the repression function of SALL4 in tumor-
suppressor transcripts, switching SALL4 from a dual-mode tran-
scription factor to single mode lacking transcriptional repression
function. To that end, we resolved the RBBp4–SALL4(1–12)
complex, determined key residues involved in the SALL4–RBBp4
binding, and designed a pharmacologic peptide (RRKFAKFQWI,
named FFW hereafter) that blocked the interaction with high
affinity, and reversed the repression function of SALL4 on target
genes. The massive up-regulation of treatment-specific transcripts
resulted in apoptosis, activation of tumor suppressors, and cell
adhesion molecules, and subsequently showed a significant effect
on inhibiting xenograft formation in mice. In addition, this report
also highlights a viable and effective strategy incorporating struc-
tural analyses to accurately design a therapeutic approach against
candidate genes that are otherwise considered undruggable.
Results
Structure of the SALL4–RBBp4 Complex. To target SALL4–NuRD
interaction, we first determined the direct binding of SALL4(1–
12) to RBBp4. We utilized the first 12 aa of SALL4 in isothermal
titration calorimetry (ITC) assays to access the binding affinity of
SALL4 to RBBp4, and found that the complex formed with a KD
of 1.04 ± 0.06 μM (Fig. 1A). These binding kinetics were further
confirmed using surface plasmon resonance (SPR), with a cal-
culated KD for binding between the SALL4 peptide and
RBBp4 of 1.5 μM (kon = 16,830 ± 460 M−1s−1; koff = 0.026 ±
0.00045 s−1) (Fig. 1B).
We next determined the crystal structure of the RBBp4–
SALL4(1–12 aa) complex to obtain structural information of
the SALL4–RBBp4 protein–protein interaction site. The com-
plex was solved at 2.7-Å resolution (SI Appendix, Table S1).
RBBp4 forms a seven-sheet β-propeller (residue 33–404) with an
N-terminal α-helix (Fig. 1C). All 12 residues of the SALL4 pep-
tide are well defined in the electron density map, with 9 of the
residues making favorable interactions with RBBp4. The substrate
binding site of RBBp4 is highly acidic, with eight glutamic acid
and two aspartic acid residues within 5 Å of the SALL4 peptide.
This negatively charged interface binds the predominantly posi-
tively charged SALL4 peptide, which has five basic residues: Arg3,
Arg4, Lys5, Lys8, and His11 (Fig. 1 D and E). Arg3 and Lys5 of
SALL4 form charged interactions with Glu275, Glu319, and with
Glu126, Glu179, respectively, in RBBp4 (Fig. 1F and SI Appendix,
Table S2). Arg4 forms a salt bridge with Glu231, whereas
His11 makes π–cation interactions with Trp42. Several unique
hydrogen bonding contacts were observed between Arg3:Lys376,
Arg4:Phe321, Arg4:Arg129, and Pro9:Ser73 of the RBBp4–
SALL4 complex (Fig. 1F and SI Appendix, Table S2). Additional
hydrogen bonds between residues Ser2 to Gln6 and Gln10 to
Ile12 stabilize the SALL4 peptide, and several hydrophobic in-
teractions stabilize the complex. The Arg4 side chain is deeply
buried into RBBp4 (buried surface area 211 Å2), whereas Lys5
and Pro9 bind in shallow grooves.
RRK Residues Are Crucial for RBBp4–SALL4 Interaction. Structural
analysis of the RBBp4–SALL4(1–12) complex revealed a large
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Fig. 1. Structure of RBBp4–SALL4(1–12) complex and their binding affinity. (A) ITC profiles of SALL4 WT peptide titrated against RBBp4 are shown in raw
(Upper) and a simulated curve in a 1:1 binding model (Lower). (B) Sensorgram of SPR demonstrated binding of SALL4 WT peptide to RBBp4 immobilized on a
dextran-coated chip. (C) Front view of the RBBp4–SALL4(1–12) complex. RBBp4 is depicted in yellow, green (β-sheet), and red (α-helix), and the SALL4 peptide
is depicted in blue. N and C termini of RBBp4 are labeled. (D) Diagram representing electrostatic potential. Acidic patches are indicated in red, neutral in
white, and basic in blue. (E) The final 2F0–Fc electron density map (contoured at 1σ) for the key residues of SALL4 peptide from Met1 to Ile-12. (F) Side chains
of RBBP4 (green) interacting with SALL4 peptide (blue) is shown in stick representation. Unique interactions of SALL4–RBBp4 are shown in the boxes.
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and shallow acidic interaction surface, suitable for developing a
peptide inhibitor to block the interaction. In this regard, we
undertook an integrated approach by combining computational
studies with biophysical assays to determine the important amino
acids for the SALL4–RBBp4 interaction. The structural analysis
of the complex indicated that Arg3, Arg4, and Lys5 of SALL4
are crucial for binding. We confirmed this structural hypothesis
using computational alanine scanning, and found that alanine
substitutions of Arg3, Arg4, and Lys5 greatly affected the binding
free energy (19, 16, and 14 kcal/mol, respectively) (Fig. 2A).
Based on the in silico analysis, we subsequently performed a
biochemical alanine scan of these residues with a series of mu-
tant peptides using a fluorescence polarization assay (Fig. 2 B
and C and SI Appendix, Fig. S1). Compared with the WT peptide
(IC50 = 1.0 μM), peptides bearing R3A, R4A, or K5A mutations
demonstrated significantly decreased IC50 values (4.5, 8.9, and
7 μM, respectively) (Fig. 2B), whereas the Q6A mutation had a
minimal effect (IC50 = 1.3 μM). Double mutations with two key
residues, R3A,R4A; R4A,K5A; and R3A,K5A; abolished the
interaction, with IC50 values noted above 100 μM, whereas
double mutants with the loss of only one key residue showed
reduced but positive binding (IC50 = 4.4 μM, 4.1 μM, and 4.7 μM,
respectively) (Fig. 2B and SI Appendix, Fig. S1). These findings
confirmed that Arg3, Arg4, and Lys5 are essential residues in-
volved in the SALL4–RBBp4 interaction.
We next selected a representative double mutant of essential
residues (MSARAQAKPQHI; MUT R3A,K5A) and compared
its effect with the WT peptide on cell viability in SNU398 HCC
cells, which express high levels of SALL4 RNA and protein (16).
While the WT peptide exerted an inhibitory effect on cell
number, the MUT peptide did not (Fig. 2D). Further qPCR
analysis revealed a threefold increase in PTEN expression (P <
0.0001) in cells treated with the WT peptide compared with
untreated cells, whereas MUT-treated cells again showed no
significant change (P value not significant) (Fig. 2E). These
findings indicate that the MUT peptide could not block the
RBBp4–SALL4 interaction and failed to release the suppressive
complex from the PTEN promoter, unlike its WT counterpart.
Optimization of a Candidate Therapeutic Peptide.After determining
the key interactions between RBBp4 and SALL4(1–12), and by
using structural data of the RBBp4–SALL4(1–12) complex as a
platform, we then undertook a peptide substrate-based approach
to design and optimize a potent inhibitor of the SALL4–RBBp4
interaction. We first determined the minimum length required
for bioactivity through a truncation analysis of the WT peptide
(SI Appendix, Table S3, peptide 1). Removing the first two N-
terminal residues, Met and Ser (SI Appendix, Table S3, peptides
2 and 3), increased the peptide binding affinity to RBBp4
compared with the WT (IC50 = 0.60 and 0.36 vs. 1.0 μM, re-
spectively); yet C-terminal truncations resulted in a marginal loss
of binding affinity (SI Appendix, Table S3) (IC50 = 1.29, 0.80, and
1.91 μM for peptides 5, 6, and 7, respectively). Removal of a key
binding residue (peptide 4) abolished the binding affinity (IC50 >
20 μM). To further improve binding potency, peptide 3 was se-
lected as the sequence template and subjected to a systematic
single-residue mutation analysis with alanine substitutions.
Substituting the nonessential residues of peptide 3 with Ala (SI
Appendix, Table S3, peptides 11–16) yielded more potent peptides,
whereas substituting the essential residues of peptide 3 with Ala
abolished binding (SI Appendix, Table S3, peptides 8–10). This
suggests that nonessential residues of peptide 3 could be replaced
with other amino acid residues for sequence optimization.
Systematic substitution of the nonessential residues (SI Appendix,
Table S3, peptide 20–45) revealed a marked reduction of IC50
upon replacement of Gln-4, Pro-7, and His-9 of peptide 3.
Gln4 sits in a small binding pocket formed by Pro43, His71, and
Glu395 of RBBp4, which is able to accommodate amino acid
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Fig. 2. Key residues involved in RBBp4–SALL4(1–12) binding. (A) Computational alanine scanning (CAS) was carried out on all 12 residues of the
SALL4 peptide. The difference in the binding free energy (ΔΔGbind) of the alanine mutants (ΔGmutant) and WT (ΔGwild type) was calculated (ΔΔGbind =
ΔGmutant − ΔGwild type). ΔΔGbind was tabulated (Left) and plotted in a bar chart (Right). (B) Alignment of mutant peptides. Mutated residues are highlighted in
red. The IC50 of each peptide, including WT, was determined by fluorescence polarization. Different concentrations of each peptide were titrated into a
mixture of 0.045 μM RBBp4 and 0.1 μM of C-labeled FITC-SALL4 WT peptide. Polarization was measured in millipolarization. (C) Representative IC50 curves of
SALL4 WT and double-mutant MUT R3A,K5A by fluorescence polarization. (D) Cell viability assays were performed on SNU398 cells treated with SALL4 WT or
MUT R3A,K5A peptides. Pep-1 carrier was added to the peptide to facilitate cellular penetration of the peptides. (E) Cells were treated with 8 mM of peptides
with Pep-1 carrier for 24 h, and transcript levels of the SALL4–RBBp4 downstream gene, PTEN, were measured using quantitative real-time PCR. Data rep-
resent mean ± SD (n = 3). N.S., not significant.
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residues with hydrophobic side chains. Consequently, substituting
Gln4 with Leu or Phe (peptides 23 and 24) led to improved
binding affinities, particularly Phe, which induced a sevenfold en-
hancement in binding affinity over that of peptide 3 (IC50 0.05 vs.
0.36 μM) (SI Appendix, Table S3). Additionally, a Phe substitution
(peptide 34) for Pro7 further increased the potency of the peptide
(IC50 0.17 vs. 0.36 μM) (SI Appendix, Table S3). Using computer
modeling, the aromatic ring of Phe7 was found to be solvent-
exposed and not involved in RBBp4 binding. However, its back-
bone amide proton could be involved in H-bonding to the side-
chain carboxyl moiety of Glu395, an interaction lacking in Pro7 (SI
Appendix, Fig. S2). In an effort to enhance the π–π interaction to
RBBp4, His9 was replaced by aromatic residues Trp (peptide 41),
and the substitution improved the binding affinity by threefold
compared with that of peptide 3 (IC50 0.12 vs. 0.36 μM) (SI Ap-
pendix, Table S3).
These three substitutions (Gln4Phe, Pro7Phe, and His9Trp)
were incorporated into peptide 46 (RRKFAKFQWI, named
FFW hereafter). Fluorescence polarization assay confirmed the
high potency of FFW, with a >43-fold increase in affinity com-
pared with the original 12-residue WT peptide (IC50 = 0.023 vs.
1.0 μM) (SI Appendix, Fig. S3 and Table S1).
FFW Reverse-Transcription Repression by SALL4–RBBp4. To elucidate
the regulatory pathways that FFW could affect, a penetratin
sequence (PEN) was attached to the N terminus of FFW to
facilitate penetration into cells in culture (Fig. 3A). The FFW
peptide is a highly basic and hydrophobic molecule. To test the
ability of FFW to penetrate cells without the penetratin se-
quence, we treated both peptides to SNU398 cells and MTT
assays were conducted after 72 h of incubation. The results
demonstrated that although FFW is hydrophobic, the FFW
peptide did not show any effect on cell viability without the
conjugation of the penetratin sequence (Fig. 3B). We have also
conjugated FITC to the amino terminus of FFW and subjected it
to fluorescence microscopy, but could not detect any uptake of
the peptide by the cells (SI Appendix, Fig. S4).
In addition to PEN-FFW, the PEN sequence was also conju-
gated to WT and MUT peptides. To test if the PEN-FFW
peptide could disrupt endogenous SALL4–NuRD interaction,
we performed coimmunoprecipitation after peptide treatment
using SALL4 antibody (Fig. 3C). We found that the endogenous
SALL4–RBBp4/HDAC/NuRD interaction was abrogated after
PEN-FFW treatment, but not the controls. We next sequenced
RNA transcripts (RNA-seq) from SNU398 cells treated with
PEN alone, and different PEN conjugated peptides (30 μM, 8 h).
Unbiased hierarchical clustering of the whole transcriptome data
revealed that the PEN-FFW–treated sample was distinctly clus-
tered away from the rest of the samples (Fig. 3D), whereas PEN-
and PEN-MUT–treated samples (controls) were closely clus-
tered together with similar transcriptome profiling, and the
PEN-WT–treated sample was clustered in between. Strikingly,
i)  PEN      : RQIKIWFQNRRMKWKK
ii) PEN-WT     : RQIKIWFQNRRMKWKK–MSRRKQAKPQHI
iii)PEN-MUT  : RQIKIWFQNRRMKWKK-MSARAQAKPQHI
iv) PEN-FFW  : RQIKIWFQNRRMKWKK-RRKFAKFQWI
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heatmap presentation of differentially expressed genes (DEGs)
demonstrated that PEN-FFW treatment induced almost exclu-
sively gene activation, in which 99.5% of the PEN-FFW DEGs
were up-regulated (575 transcripts) and only 0.5% of the DEGs
(three transcripts) were down-regulated (Fig. 3E and Dataset
S1). This indicate that the PEN-FFW treatment had reversed the
repressive function of SALL4, switching it from a dual-action
transcription factor to a single-activator mode. This observa-
tion was further confirmed by M-A plot (log fold-change versus
log mean intensity) of PEN-FFW versus controls (Fig. 3F), in
which a majority of the DEGs are up-regulated.
Next, gene set enrichment analysis (GSEA) was performed using
the whole transcriptome between PEN-FFW or PEN-WT and the
two negative controls (PEN and PEN-MUT), respectively. GSEA
analysis revealed a significant concordance between genes up-
regulated in cells treated with PEN-FFW and genes down-
regulated by overexpressing oncogenes like KRAS and ALK (Fig.
3G and Datasets S2 and S3). Genes down-regulated in HCC, for
example ATP1A2 and LCN8, were also specifically up-regulated in
PEN-FFW–treated samples, while further analysis showed that
targets of HNF4a, a key liver transcription factor, were also
enriched in PEN-FFW–treated cells. Interestingly, PEN-FFW–
enriched genes were associated with the repressive H3K27Me3
mark before peptide treatment, indicating these transcripts had
undergone epigenetic modulation following disruption of the
SALL4–NuRD interaction. (Fig. 3G and Dataset S3).
SALL4–RBBp4 Disruption Induced Apoptosis and Enhanced Cell Adhesion.
Next, we conducted chromatin immunoprecipitation coupled with
next-generation sequencing (ChIP-seq) on SNU398 cells to de-
tect the SALL4 binding regions in the genome to compare with
the PEN-FFW DEGs. Of the 7,883 SALL4 binding peaks, 60%
are located at promoter regions, with H3K27Ac marks enriched
around the SALL4 peaks (Fig. 4A). Interestingly, 57 of the 575
PEN-FFWDEGs have strong SALL4 binding peaks within 2 kb of
the transcription start sites, suggesting that these transcripts are
direct targets of the SALL4–RBBp4/NuRD interaction (Fig. 4B).
Furthermore, we observed that chromatin remodelers and tran-
scripts encoding molecules that facilitate transcription activation
are among the highest expressed DEGs of these 57 transcripts
(Fig. 4C). These include: POLR2A, the largest subunit of POLII;
pre-mRNA splicing factor SRRM2; and chromatin remodeling
protein SRCAP. Interestingly, both of the H3K4-specific methy-
transferases, MLL2 and SETD1B, also demonstrate promoter
occupancy by SALL4 (Fig. 4D) and up-regulation after SALL4–
RBBp4/NuRD disruption, implying that the SALL4–RBBp4/
NuRD complex strongly regulates chromatin status.
A significant proportion of the PEN-FFW DEGs are miRNA
and noncoding RNAs (23% of the transcriptome). We focused
on annotated transcripts and performed pathway analysis for
these transcripts. Intracellular Ca2+ concentration is tightly regu-
lated in cells. An unexpected finding of the pathway analysis
revealed that a group of transcripts involved in calcium signaling,
such as calmodulin (CALML6) andGRIN1, are up-regulated (Fig.
4E), suggesting that SALL4–RBBp4 disruption might induce a
Ca2+ influx in PEN-FFW–treated cells. Because Ca2+ could act as
a secondary messenger to activate apoptosis (23), we detected
transcripts encoding molecules involved in the apoptosis pathway,
such as CARD14, RAPSN, CHRNG, and BCL2L14, in the PEN-
FFW DEGs. To further investigate the effect of these gene
changes, three liver cancer cell lines with high expression of
SALL4, SNU398, Huh7, and Hep3B (16) were treated with dif-
ferent peptides for 6 h (SI Appendix, Fig. S5) or 24 h (Fig. 4F). The
cells were stained with propidium iodide (PI) and anti-Annexin V
antibody to assess the apoptotic cell population by flow cytometry.
After 24 h, PEN-FFW treatment significantly increased the apo-
ptotic population (PI+/Annexin V+, Annexin V+) from 16.6% in
PEN control to 32.5% after PEN-FFW treatment in SNU398
(Fig. 4 F, i); from 14.3% in PEN control to 73.5% in PEN-FFW
treated Huh7 cells (Fig. 4 F, ii); and from 13.5% in PEN control
to 51.7% in PEN-FFW treated Hep3B cells (Fig. 4 F, iii), sup-
porting previous data from transcriptome analysis.
Loss of cell–cell or cell–extracellular matrix (ECM) contact is
often observed in cancer as transformed cells gain motility and
invasiveness. In contrast, gain of cell–cell and cell–ECM contact
could inhibit cancer cell growth and prevent metastasis. In our
transcriptome analysis, the most distinct cellular pathway asso-
ciated with PEN-FFW DEGs were transcripts encoding mole-
cules involved in cell–cell adhesion and ECM interactions,
including CDH4, Claudin-5, -18, and -20, collagen (COL4A4,
COL5A1), integrin (ITGA10), laminin (LAMA5), and vitronectin
(VTN). Furthermore, a group of cadherins were also up-
regulated (CDH4, FAT2, PCDH12, PCDHAG12) after PEN-
FFW treatment. We therefore hypothesize that the disruption
of SALL4–RBBp4 could tighten cell–cell contacts and limit
mobility of these cells. To examine this hypothesis, we performed
a cell-invasion assay in Boyden chambers in which serum-starved
SNU398, Huh7, or Hep3B cells were treated with different
peptides (10 μM). Cells migrating toward 10% serum and in-
vading the membrane pores after 24 h were stained with DAPI,
and quantified by counting cells per microscope field-of-view.
Compared with PEN- and PEN-MUT–treated cells, cell migra-
tion ability was indeed markedly impaired in PEN-FFW–treated
cells. For both SNU398 and Huh7, more than an 85% reduction
of migrated cells was observed in the PEN-FFW–treated group,
compared with PEN (Fig. 4G) (P < 0.001 and P < 0.0001, re-
spectively). For Hep3B, the migration activity is low compared
with the other two cell lines, in which only 44 cells were found to
have passed the membrane after PEN treatment, and this number
dwindled to 14 cells after PEN-FFW treatment. Wound-healing
assays were also performed to assess the migration activity of
PEN-FFW–treated cells. We found that PEN-FFW–treated cells
had slower migration activity compared with PEN-MUT and
PEN controls in SNU398 (Fig. 4H), Huh7, and Hep3B cells (SI
Appendix, Fig. S6).
Beside the pathways mentioned previously, a class of tumor
suppressor genes was also restored after PEN-FFW treatment
(Fig. 4E). TSC1/2, which inhibits mTORC1 (24), was enriched
2.5-fold after PEN-FFW treatment (Dataset S1). Another ex-
ample, LRRC4, which functions to delay cell cycle progression
(25), was increased after PEN-FFW treatment. A negative reg-
ulator of RAS, DOK3, was also found up-regulated in the PEN-
FFW treated cells. Taken together, our data suggest that the
disruption of the SALL4–RBBp4 interaction by the PEN-FFW
peptide could lead to up-regulation of cell adhesion molecules to
suppress migration, Ca2+ influx to induce apoptosis, and a group
of tumor suppressors that oppose various oncogenic processes.
Prognostic Value of PEN-FFW Up-Regulated Genes. Because PEN-
FFW treatment leads to significant apoptosis of SNU398 liver
cancer cells (Fig. 4F) and dramatic inhibition of xenograft tumor
growth (as presented below; see also Fig. 6), we were interested
in evaluating the potential prognostic value of these PEN-FFW
up-regulated DEGs in patients. Thus, we first overlapped these
up-regulated genes with genes that are significantly up-regulated
in normal liver samples compared with liver cancer patients in
three independent cohorts (Fig. 5A, schematic representative of
the analysis). Across the three cohorts, 26 of these PEN-FFW
up-regulated DEGs show consistent overexpression in adjacent
nontumor samples compared with the tumor (Fig. 5B and
Dataset S4). We next explored their diagnostic abilities in sep-
arating HCC samples from normal tissues using the receiver
operator curve (ROC), and were able to identify nine of them
with consistently high area under curve across all three cohorts
(Dataset S5). Three examples of these genes (IGFALS, GNAO1,
and ECM1) are depicted in Fig. 5C.
Concomitantly, to further evaluate the prognostic relevance of
these 26 PEN-FFW up-regulated DEGs, we examined their
survival differences in two independent HCC cohorts. We were
able to identify eight genes with favorable survival difference for
the patients with high expression compared with those with low
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expression (Fig. 5A and Dataset S6). By overlapping the two
gene sets from ROC and survival analysis, we were able to
identify four PEN-FFW up-regulated DEGs having both high
diagnostic and high prognostic values, and they are IGFALS,
SLC22A1, ASPG, and FTCD. The favorable survival difference
from these four genes is depicted in Fig. 5D, using two in-
dependent cohorts. The prognostic value and diagnostic value of
these four genes are highlighted in bold in Datasets S5 and S6.
Therapeutic Peptide FFW Leads to Tumor Regression in Xenograft
Models. Having developed the highly potent FFW peptide af-
fecting SALL4 transcription, we next compared its efficacy to
WT and mutant peptides at the cellular level. SNU398 cells were
treated with PEN-MUT, PEN-WT, and PEN-FFW for 72 h with
a series of concentrations, and cell viability was measured with
the MTT assay. We observed that PEN-FFW conferred a 4-fold
improvement in reducing cell viability compared with the PEN-
WT (Fig. 6A) (EC50 7.6 μM vs. 30 μM, respectively), and more
than 13-fold compared with PEN-MUT (EC50 > 100 μM). To
further confirm the specific therapeutic effect of PEN-FFW in
SALL4-expressing HCC cells, we employed SNU398, Huh7, and
Hep3B, three HCC lines with high levels of SALL4 (16);
SNU387, a HCC line with undetectable levels of SALL4; and
THLE-2 and THLE-3, immortalized normal liver epithelial cell
lines with undetectable levels of SALL4, and treated these cells
with PEN-MUT, PEN-WT, or PEN-FFW peptides (SI Appendix,
Fig. S7). Our data demonstrate the specificity of PEN-FFW in
targeting SALL4-high HCC cells (SNU398, Huh7, and Hep3B),
and not SALL4-low HCC cells (SNU387) or immortalized nor-
mal liver epithelial cell lines THLE-2 and THLE-3, highlighting
a clear therapeutic window for treatment.
To further test the therapeutic effect of PEN-FFW in vivo,
SNU398 cells were implanted subcutaneously into the flanks of
NOD/SCID/γ-mice (NSG), and the mice were randomly grouped
for peptide treatments (n = 5 per group) (Fig. 6B). For mice
treated with PEN (control) or PEN-MUT, tumors progressively
increased in size, showing that neither peptide was able to inhibit
tumor growth (Fig. 6C). In contrast, although PEN-WT impaired
tumor growth (P = 0.001), PEN-FFW induced a much stronger
therapeutic effect (P = 0.0008) with a tumor growth inhibition of
N
o.
 o
f c
el
ls/
fie
ld
(ii) Huh7
P < 0 . 0 0 0 1 * * * *
PEN        PEN-FFW
150
100
50
0
< . 1**
*
500bp1000bp
SETD1B
1000bp
SRCAPD
C
SRRM2
MLL2
SRCAP
POLR2A
SETD1B KCNQ1OT1PE
N
-F
FW
 D
EG
s w
ith
 
SA
LL
4 
Ch
IP
pe
ak
s
Expression Value
10      100      1000    10000  100000
MLL2
A B
(N= 7049)
6992 57 518
SALL4 ChIP peaks
FFW enriched 
genes (N= 575)
Cell-cell 
adhesion/
Extra 
cellular 
matrix
CDH4
CLDN1
L1CAM
MADCAM1
SELL
CNTN2
NCAM1
COL4A4
COL5A1
ITGA10
LAMA5
VTN Tumor 
suppressors
TSC1
CDH4
DOK3
LRRC4
NR4A3
AMH
PTPN23
TAGLN
CREB3L1
TNK1
Apoptosis
BCL2L14
CARD14
CRHR2
GALR2
CAPN12
PDZD2
E
MLL2
POLR2A
SRCAP
SRRM2
SETD1B
Ca2+
CALML6
ATP2A1 PHKG2
GRIN1
PRKCA CACNG8
Transcription 
Activation
SALL4-RBBp4 
disruption
F
G (iii) Hep3B
N
o.
 o
f c
el
ls
PEN        PEN-FFW
50
40
30
20
10
0
(i) SNU398
P < 0 . 0 0 1 * * *
PEN        PEN-FFW
N
o.
 o
f c
el
ls/
fie
ld
80
60
40
20
0
P< 01 **
H
Day 0
Day 3
PEN PEN-FFW PEN-MUT
SALL4 H3K27Ac
-5k    0     5k -5k    0     5k
PEN-FFW
(iii) Hep3B
(i) SNU398
(ii) Huh7
PEN control
13.7 %
0.1 %
83.3 %
2.9 %
3.5 %
82.2%
6.9 %
7.4 %
0.4 %
86.1%
6.0 %
7.5 %
20.1%
12.4 %
1.1 %
66.4 %
70.0%
3.5 %
14.7 %
11.8 %
44.1%
7.6%
2.2 %
46.2 %
PI
Annexin V
10
2 
   
 1
03
10
4
10
5
102         103 104 105 102         103 104 105
10
2 
   
 1
03
10
4
10
5
10
2 
   
 1
03
10
4
10
5
10
2 
   
 1
03
10
4
10
5
102         103 104 105 102         103 104 105
102         103 104 105 102         103 104 105
29.8
0
18.16
0
12.90
0
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85%. PEN-FFW–treated mice also displayed the smallest tumors
(Fig. 6D), with significantly lower tumor weight (μ = 88 mg in
PEN-FFW, μ = 564 mg in PEN-WT, and μ = 1,550 mg in PEN
control) (Fig. 6E). To access toxicity, we tabulated the body
weight of the mice at end point (SI Appendix, Fig. S8) and also
traced the body weight change throughout the experiment, and
found no significant difference, suggesting the overall well-being
of the mice receiving the peptide treatments.
To benchmark against current therapy used in advanced stage
HCC, we compared PEN-FFW–treated SNU398 tumor xeno-
grafts to that of Sorafenib-treated xenografts in a separate set of
experiments (SI Appendix, Fig. S9) (n = 6 per treatment group).
Interestingly, PEN-FFW treatment resulted in stronger antitu-
mor activity than Sorafenib compared with vehicle-treated groups,
albeit not statistically significant. Furthermore, mice treated with
PEN-FFW in combination with Sorafenib showed the slowest rate
of tumor growth. These data suggest a potential therapeutic effect
of PEN-FFW in treating HCC patients, including those refractory
to Sorafenib treatment. To further test this hypothesis, we de-
veloped a second xenograft model with a chemo-resistant HCC cell
line, PLC8024, which is both SALL4+ and CD133+, and also radio-
resistant (26, 27) (n = 6 per treatment group). In this chemo-
resistant model, we observed greater tumor growth (+1.5-fold) in
the Sorafenib-treated group compared with the vehicle control
group (Fig. 6F). Although PEN-FFW treatment showed minimal
tumor inhibitory effect in this model, a significant synergistic effect
of Sorafenib and PEN-FFW was observed in mice treated with
both agents (P = 0.02, tumor growth inhibition 57% and 73%
compared with control and sorafenib treated group, respectively)
(Fig. 6F). This result further suggests that PEN-FFW alone, or as
part of combination therapy, could bring clinical benefits to ad-
vanced stage HCC patients to overcome resistance to Sorafenib.
Drug-Like Properties of FFW. Biologics or compounds rapidly de-
graded in plasma generally demonstrate little efficacy in vivo. To
further evaluate the potential of further development of PEN-
FFW as a drug candidate, we examined the plasma stability,
cell-penetration kinetics, and toxicity of the peptide. First, we
monitored the degradation of PEN-FFW (1 μM) in de-identified,
healthy human plasma by LC-MS/MS. At 30-min incubation (Fig.
7A, Inset), more than 90% of the peptide remained in the plasma.
In comparison, the compound Eucatropine as a control was
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Fig. 5. PEN-FFW DEGs predicted favorable outcome for HCC patients. (A) Schematic representation of the integrated analysis of treatment data with patient
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rapidly degraded to 40% (SI Appendix, Fig. S10, Inset). Extending
the experiment duration by 24 h revealed more than 50% of the
peptide remained intact in the plasma after 4 h, gradually de-
creasing to ∼20% on the 24th hour (Fig. 7A). This suggests that
PEN-FFW can potentially be developed as an intravenous drug.
We subsequently conjugated FITC to the N terminus of PEN-
FFW to assess the permeability and stability of the peptide in
cells. Live cell imaging was performed on the treated cells at 2-min
intervals for the first hour, and at 5-min intervals for the sub-
sequent 23 h. It was observed that FITC-PEN-FFW entered cells
by 18 min, and translocated to the nucleus by 22 min. At 2.5 h,
FITC-PEN-FFW had entered every cell in the microscopic field,
with incremental FITC-signals at 24 h (Fig. 7B and Movie S1).
Finally, potential toxic effects of the peptide were assessed with
C57BL/6 mice harboring an intact immune system (n = 4). The
mice were exposed to intraperitoneal administration of PEN-FFW
(30 mg/kg) or vehicle (10% DMSO) every alternate day over the
course of 17 d to a cumulative dose of 270 mg/kg. Mice in both
groups remained alert, responsive, and did not exhibit notable
signs of toxicity, such as lethargy, loss of mobility, or weight loss
(Fig. 7C). After a 7-d washout period, complete blood counts and
liver-function assay tests were performed, and organs were har-
vested for histology. To access potential liver injury caused by the
peptide treatment, serum AST (aspartate aminotransferase) and
ALT (alanine aminotransferase) levels were tested. Elevation of
the two enzymes was not observed in the treatment group (Fig.
7D), indicating no liver damage was detected following treatment.
Concurrently, no significant change in blood counts (Fig. 7E) or
tissue damage (Fig. 7F) was observed in the treatment group
compared with the control group.
Discussion
HCC is a deadly disease that lacks treatment options and al-
ternative therapeutic approaches are urgently needed. In this
report, we present our strategy to target HCC. We have previously
found that SALL4 is elevated in a subclass of HCC enriched with
hepatic progenitor cell features (16), and patients with this subtype
suffer from a poor prognosis. RBBp4 is an essential subunit of
NuRD complex, which in turn plays a key role in maintaining si-
lencing of key regulators during embryonic development. A
deregulated SALL4–RBBp4/NuRD pathway results in silencing of
tumor suppressors, such as PTEN in HCC cells. Therefore, targeting
the SALL4–NuRD pathway in HCC is a promising therapeutic
approach. To further understand the mechanism of interaction, we
first determined the crystal structure of the RBBp4–SALL4(1–12)
complex. The crystal structure revealed a large, acidic interaction
surface between the two nuclear factors, with side chains of the
SALL4(1–12) peptide intercalating into the grooves of RBBp4,
providing an opportunity for an engineered peptide to competitively
inhibit the interaction (Fig. 8A). An integrated approach combining
computational analysis, rational truncation, and systematic sub-
stitution studies was undertaken to design the therapeutic peptide.
This approach facilitated the testing of peptide affinity down to
single amino acid resolution, and provided real-time data feedback
to the modeling, enabling further sequence enhancement. Using this
approach, we were able to develop a potent SALL4–RBBp4/NuRD
inhibitor that inhibits tumor growth in xenograft mouse models,
targeting the “undruggable” nuclear factor.
Remarkably, the disruption of SALL4–RBBp4 with the FFW
therapeutic peptide resulted in massive up-regulation of tran-
scripts, which is very different from previous reports in which
SALL4 was knocked down (16). SALL4 can both repress and
activate genes, and down-regulation of SALL4 leads to both up-
and down-regulation of its target genes. In contrast, within the
observed time period, FFW peptide treatment caused a unidi-
rectional transcription activity shift toward only up-regulation of
target genes (Fig. 8B). We hypothesize that in cancer cells,
reactivation of SALL4 causes repression of tumor suppressors
and epithelial markers like cadherins, resulting in a progenitor-
like, undifferentiated cancer cell type. Upon peptide disruption
of the SALL4–RBBp4 axis, the repression of SALL4 function is
released and results in mass activation of transcripts unfavorable
for cancer cell survival but beneficial to patient survival.
In the transwell cell migration assay, it was demonstrated that
PEN-FFW–treated cells have impaired cell migration compared
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Fig. 6. Antitumor activity of the candidate therapeutic peptide FFW. (A) Penetratin-conjugated peptides were subjected to the cell viability assay in
SNU398 cells, demonstrating the high potency of PEN-FFW. TSA (Trichostatin A) was used as positive control to reduce cell viability. (B) 7.2 × 105 SNU398 cells
were inoculated subcutaneously into the right flank of NSG mice. Tumors grew for 1 wk before peptide treatment was administered on alternate days for a
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day 17. (E) Tumor weight of mice from C (n = 5 per group): PEN-FFW, μ = 88.34 mg; PEN, 1,550.78 mg; PEN-MUT, 1,273.46 mg; PEN-WT, 563.46 mg. Data
represent mean ± SD (n = 5). The experiments were performed twice independently; representative data from a single experiment are shown. (F) NSG mice
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with controls, and this phenotypic change corresponds to the up-
regulation of transcripts encoding cell adhesion molecules and
cadherins. Similar to knocking down SALL4, the disruption of
SALL4–RBBp4 resulted in apoptosis (16). Together with the up-
regulation of tumor-suppressor transcripts, the overall tran-
scriptome change brought by FFW is at a disadvantage to tumor
progression. Simultaneously, these transcripts are associated
with a good prognosis in HCC patients, as shown by survival
analysis.
The use of peptides as drugs may hold significant advantages
over small molecules in targeting of protein–protein interactions,
as large binding surfaces typically lack defined or deep binding
pockets (28, 29). Thus, we chose to target the SALL4–RBBp4
protein–protein interactions using a peptide due to the large and
predominantly shallow binding interface between SALL4 and
RBBp4. Moreover, a well-designed peptide drug tends to possess
higher selectivity with a safer toxicity profile compared with small
molecules. In certain therapeutic areas in which small molecules
have limited success, peptides have been shown to be valuable
substitutes. For example, the development of protease-resistant
stapled peptides with cell-penetrating capabilities (30) and new
peptide formulations that enhance their oral bioavailability (31)
have resulted in a dozen peptides in clinical trials and tens of
approved peptide drugs (29). We tested the stability of PEN-FFW
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in human plasma, and the results demonstrated notable stability in
which 90% of the peptide was retained after 30-min incubation
under physiological conditions, gradually decreasing over time with
20% still intact at 24 h. This stability profile indicates a possibility
to develop an intravenous delivery route for FFW. One advantage
of using peptides as drugs is minimal toxicity. The suitability of
further developing FFW is further supported by the low toxicity
profile of FFW in C57BL/6 mice.
PEN-FFW is a specific SALL4–RBBp4/NuRD inhibitory pep-
tide targeting SALL4+ HCC by binding to RBBp4. This represents
a first attempt to target RBBp4, a chaperone protein with WD40-
repeats. In the nucleus, the RBBp4/NuRD complex binds to a few
other lineage-specific proteins, such as BCL11B and FOG1. Sev-
eral crystal structures of RBBp4 with its binding partners have
been reported previously, including BCL11A (32), FOG-1 (33),
and PHF6 (34). However, in the context of HCC cells, these
molecules are not present or are expressed at very low abundance.
Hence, we hypothesize that RBBp4/NuRD binds to different
molecules in a cell-type–specific manner, and with this, the PEN-
FFW peptide is specific to SALL4–RBBp4 binding in HCC cells.
A deregulated SALL4–RBBp4/NuRD pathway results in si-
lencing of tumor suppressors in HCC cells. The SALL4–RBBp4/
NuRD interaction represents an exciting target in HCC, and
unlike HDAC inhibitors, which target cells nonselectively, this
SALL4–RBBp4/NuRD interaction has been observed to be ex-
clusive to cancer cells that express SALL4. It is worth mentioning
that RBBp4 is present in other nuclear complexes, such as
PRC2, MLL2, and Sin 3, functioning as a chaperone. It is pos-
sible that blocking RBBp4 could disrupt the formation of these
general nuclear complexes in a cell-type–independent manner.
Further investigations will need to be carried out to understand
how the peptide would affect these complexes.
Through resolving the structure of the RBBp4–SALL4(1–12)
complex, identification of the key interacting residues, and sys-
tematic peptide studies, a potent therapeutic peptide, FFW, was
demonstrated to confer robust proapoptotic and antimigration
effects in SALL4-expressing HCC cells, and induced marked
improvement in therapeutic efficacy in mice bearing hepatocel-
lular carcinoma tumors. Mechanistically, global genomic studies
revealed that this FFW could convert SALL4 from a dual-
regulator to an activator-only status. Overall, the FFW peptide
could be the basis for development of a first-in-class drug, as
there is currently no available inhibitor targeting the SALL4–
RBBp4/NuRD interaction, and in addition, provide a viable
therapeutic strategy for the significant subset of patients with
HCC and many other cancers whose malignancies are driven
by SALL4 expression.
Methods
Crystallization screens were performed with the hanging-drop vapor-
diffusion method using Hampton Research screens. The RBBP4 protein was
purchased from SinoBiological and concentrated to 8 mg/mL in 50 mM Tris
100 mM NaCl. The concentrated RBBP4 protein was mixed with 20 mM of
SALL4 peptide and crystallization drops were set up at a 1:1 ratio. Diffrac-
tion quality crystals of SALL4(1–12) –RBBp4 complexes were obtained from a
reservoir solution containing 0.2 M sodium chloride, 0.1 M Bis-Tris, pH 5.5,
25% PEG 3,350. Detailed protocol of crystallization and structure de-
termination can be found in SI Appendix, SI Material and Method.
Detailed protocols for ITC, SPR, flourescence polarization, computational
alanine scanning, cell culture and treatment with peptide, coimmunopreci-
pitation, migration and wound-healing assay, xenograft studies, plasma
stability assay, live cell imaging, RNA-seq data analysis, ChIP, and ChIP-seq
analysis can also be found in SI Appendix, SI Material and Method. All animal
studies were conducted with the approval of the Institutional Animal Care
and Use Committee (IACUC) of the National University of Singapore.
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